Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Providence College · Women & Infants Hospital of Rhode Island · +26 more institutions
Abstract
PURPOSE In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986 ), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 (BRCA) mutation. We report overall survival (OS) after a 7-year follow-up, a clinically relevant time point and the longest follow-up for any poly(ADP-ribose) polymerase inhibitor in the first-line setting. METHODS This double-blind phase III trial randomly assigned patients with newly diagnosed advanced ovarian cancer and a BRCA mutation in clinical response to platinum-based chemotherapy to maintenance olaparib (n = 260) or…
Citation impact
- FWCI
- 42.74
- Percentile
- 100%
- References
- 20
Authors
23- PDPaul DiSilvestroCorresponding
Providence College, Women & Infants Hospital of Rhode Island
- SBSusana Banerjee
Royal Marsden NHS Foundation Trust, Institute of Cancer Research
- NCNicoletta Colombo
University of Milan, European Institute of Oncology
- GSGiovanni Scambia
Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico
- BKByoung‐Gie Kim
Samsung Medical Center, Sungkyunkwan University
Topics & keywords
- Olaparib
- Medicine
- PARP inhibitor
- Internal medicine
- Ovarian cancer
- Hazard ratio
- Clinical endpoint
- Oncology
- Good health and well-being